New Alzheimer's survey shows most in state want early detection
The Brief
The new 2025 Alzheimer's Association Facts and Figures Report shows the projected number of Americans living with Alzheimer's has grown to 7.2 million.
79% of adults in a new survey of 1,700 people say they would want to know if they had the brain disease before they started exhibiting symptoms.
92% of adults say they'd want access to new FDA approved drugs to slow the progression of the disease.
(FOX 9) - The Alzheimer's Association released its 2025 Facts and Figures Report showing the number of people living with Alzheimer's disease has reached 7.2 million Americans, topping the 7 million threshold for the first time.
What we know
According to the report, the number of Minnesotans living with Alzheimer's has remained stable at 102,000.
However, the brain disease has now jumped from the sixth leading cause of death in Minnesota to number four.
"When I started back in this organization, I think we were still at 5 million and now that we're at 7 million, that's scary to me," said Susan Parriott, CEO of the Alzheimer's Association of Minnesota – North Dakota. "That's a big number. So, we need to stand up and do something about this."
What's new
In conjunction with the Facts and Figures Report, this year the Alzheimer's Association released the results of a national survey of 1,700 adults.
One of the important findings is that 79% said they would want to know if they had Alzheimer's before they developed symptoms. It's a new revelation as the FDA has approved two new drugs, Leqembi and Kisunla, to slow the progression of the plaques in the brain that lead to the disease.
The survey also found that 92% would want access to those drugs.
Another nine of 10 want to see a blood test to detect Alzheimer's.
Local perspective
The Donahue family in Faribault, Minnesota, is one of the many families hoping for positive results from the new drugs.
Julie Donahue's husband, Tim, was diagnosed with early-onset Alzheimer's at 55 years old. They sought out a cognitive test for Tim after a pattern of confusion in tracking down a lost item.
"I did not expect it at all," said Julie of the diagnosis. "He had a history of cancer, and I thought it was the cancer coming back. I had no idea it was Alzheimer's."
The two new drugs are showing initial results in patients who are using them.
Julie says Tim's Leqembi treatments have led to a 30% reduction in his amyloid pacque.
"We are talking about slowing the disease progression by, say, 30% over an 18- month period," said Dr. Ronald Petersen, a neurologist at Mayo Clinic in Rochester. "What that translates to patients is, we try to keep them stable, perhaps for another five, six, seven months at their current level of functioning. Maybe as the drug goes out longer, say to 36 months, we might be buying nine, 10, 11 months of stability."
These drugs are not a cure, but they're buying families time.
For Tim and Julie Donahue, it's buying more precious moments with their grandchildren.
For an extended interview with Dr. Petersen on the new Alzheimer's drugs, please go to the Fox 9 YouTube channel.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
31 minutes ago
- Business Insider
Sarepta suspends non-ambulatory Elevidys shipments after second death
Sarepta (SRPT) Therapeutics provided a safety update regarding Elevidys, an FDA approved gene therapy for patients with Duchenne muscular dystrophy. The company announced a second reported case of acute liver failure resulting in death. The cases of ALF to date have both occurred in non-ambulatory individuals with Duchenne. Sarepta is temporarily suspending shipments of Elevidys for non-ambulatory patients while an enhanced immunosuppressive regimen is evaluated, discussed with regulatory bodies, and put in place. For ambulatory patients, no treatment changes are being proposed and the current practice of administering corticosteroids before and after Elevidys infusion, along with post-treatment monitoring, remains the same. Sarepta has also voluntarily paused dosing in the ENVISION clinical study. FDA concurs with this action, the company said. 'The pause will allow for the evaluation of a protocol amendment to incorporate an enhanced immunosuppressive regimen for the non-ambulatory patient cohort and incorporate any additional feedback from the FDA. Regulatory alignment is needed before screening and dosing in ENVISION may resume,' Sarepta added. The company is working to immediately convene an independent group of leading experts in Duchenne and liver health to consider an enhanced immunosuppression regimen for Elevidys.
New York Post
2 hours ago
- New York Post
Most people are guilty of doing this in the shower — but experts warn it's incredibly dangerous: ‘Don't do it'
What you do in the shower is your business, but the one thing experts are warning you to stop doing while sudsing up: peeing. One healthcare expert shared in a now-viral TikTok with over 1 million views that emptying your bladder while standing in the shower can be damaging — especially for women. Advertisement 'Hot take but don't pee standing up in the shower or anywhere for that matter. Ladies, you are training your bladder that it's okay to empty while standing. Don't do it! This could cause bladder leakage,' @kingsley.502 wrote as her caption. As expected, people ran to the comment section to share their opinions on this advice. 'My body created a human… I'm gonna let her tinkle wherever she likes,' one commenter wrote. Advertisement 'I can't even enjoy the simple pleasures in life,' shared another frustrated person. 'Meanwhile sitting for too long messes with our pelvic floor. So what actually is ok anymore?' said someone else, making a valid point. Many people in the comments of the viral TikTok video were upset to learn of this news. uduhunt – It's no surprise that this news is upsetting for many, considering almost a quarter of Americans admit to peeing in the shower regularly, according to a survey. Advertisement Unfortunately for these multitasking people, @kingsley.502 wasn't far off with her opinion on shower peeing — as other experts backed up her claims. 'It is one, not very hygienic, but more important than that, it will destroy your pelvic floor, and also it might create mental associations where you hear water running and all of a sudden you need to run to the bathroom,' Houston-based OB-GYN Emma Qureshey explained in a TikTok. And standing while peeing is not only unhealthy for women — it's also dangerous for men. Advertisement Since the pelvis and spine muscles are most relaxed when sitting, Gerald Collins, a consultant urological surgeon at Alexandra Hospital in Cheshire, England, said that 'Sitting is probably the most efficient way of doing it [peeing]' the doctor explained, Standing while urinating also puts men at risk for benign prostatic hyperplasia — which occurs when the prostate gland and surrounding tissue expand, obstructing the urethra. Sadly, for many men, the thought of sitting while peeing is looked down upon. In Germany, those who don't stand to relieve themselves are called 'Sitzpinkler' — a slur implying they are 'wimpy or effeminate.'
The Hill
5 hours ago
- The Hill
How Kennedy's overhaul could make vaccines more expensive
Health and Human Services Secretary Robert F. Kennedy Jr.'s moves to upend decades of vaccine policy could hit patients hardest in their wallets, as shifting guidance over shots could make insurance coverage confusing and scattershot. For decades, the Centers for Disease Control and Prevention's (CDC) independent advisory panel recommended which shots Americans should get and when. The Affordable Care Act requires all insurance companies to cover, for free, all vaccines the panel recommends. Those recommendations also help states decide which shots should be mandated for schoolchildren. Kennedy's most recent move to purge the entire advisory panel and replace them with his own handpicked members, including several vocal vaccine critics, is throwing that process into doubt. 'If we have a system that has been dismantled — one that allowed for open, evidence-based decisionmaking and that supported transparent and clear dialogue about vaccines — and then we replace it with a process that's driven largely by one person's beliefs, that creates a system that cannot be trusted,' Helen Chu, a newly ousted member of the panel and professor of infectious disease at the University of Washington School of Medicine, said during a press conference. Vaccine prices vary, but without insurance, coronavirus vaccines can cost nearly $150, the MMR shot ranges from $95 to nearly $280, and the HPV vaccine can exceed $300, according to CDC data. Individual pharmacies could charge even more. Candace DeMatteis, policy director at the Partnership to Fight Infectious Disease, said she worries about creating a two-tiered system. 'Out of pocket costs for vaccines become an issue where we could end up with a system where some people can afford vaccinating themselves and their families and others cannot,' DeMatteis said. Prior to enactment of the Affordable Care Act, vaccine coverage varied significantly depending on the type of insurance a person had. If the CDC's Advisory Committee on Immunization Practices (ACIP) changes recommendations for existing vaccines or doesn't recommend new ones, maintaining access will be difficult. 'It's a seismic shift, if you will, away from facilitating access by removing coverage and cost barriers, to one where there's great uncertainty and coverage and cost issues become barriers,' DeMatteis said. It's not clear what the vetting process was for the eight people Kennedy appointed to the ACIP, or how prepared they will be for their first meeting, which is scheduled to occur in less than two weeks. According to a Federal Register notice, the panel is scheduled to vote on recommendations for COVID-19 vaccines as well as meningococcal, HPV, influenza, and RSV vaccines for adults and maternal and pediatric populations. Health experts said they have serious questions about what direction the new panel will take and whether Americans will still have access to free vaccines, including the coronavirus shot, in time for fall respiratory season. If the ACIP is no longer a reliable, independent authority on vaccines, it 'will be replaced by a patchwork of different policies by different states, and each state will have to make its own decisions,' Chu said. 'Washington state is a place where we have experts and scientists who work together. There are other states where this may not exist, or where they may not choose to recommend vaccines. So that is going to create a lot of chaos,' she added. Some state health officials have already begun taking steps in that direction. The Illinois Department of Health said on social media it will be convening its own vaccine advisory committee and national experts 'to ensure we continue to provide clear, science-backed vaccine guidance for our residents.' When Kennedy unilaterally changed the COVID-19 vaccine guidance earlier this month to remove recommendations for pregnant women and change the open recommendation for children, the Wisconsin Department of Health Services said it would continue to recommend the shots for every person at least 6 months old. 'The recent changes in CDC guidance were not made based on new data, evidence, or scientific or medical studies, nor was the guidance issued following normal processes,' the agency said in a statement. Tina Tan, president of the Infectious Diseases Society of America, said her organization as well as other major medical groups including the American Medical Association and the American Academy of Pediatrics Academy have been speaking with insurance companies to urge them to continue paying for shots, even if the panel changes recommendations. Tan mentioned an initiative launched in April by a group of public health experts called the Vaccine Integrity Project, which is working to create an alternative process to maintain vaccine access. The initiative is funded by a foundation backed by Walmart heiress Christy Walton and led by Michael Osterholm, director of the University of Minnesota's Center for Infectious Disease Research and Policy. Federal law is specific that insurance provisions are tied to the ACIP. Specialty organizations may have expertise to make their own recommendations, but they will still require the cooperation of insurance companies. States are also more limited, and they don't have the same power as the federal government to force coverage. 'I think it remains to be seen what the insurers are going to do,' Tan said. 'However, hopefully, with the discussions going on, they can get the insurers to understand that vaccines are extraordinarily safe and effective and are the best tool that we have to protect persons of all ages against serious vaccine preventable diseases.'
